Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05492695 · ClinicalTrials.gov registry record · Phase 4
Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research Study
A Phase 4 study, sponsored by Diamond Headache Clinic.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT05492695: Clinical Trial Phase 4 study, sponsored by Diamond Headache Clinic.
NCT05492695 is a Phase 4 study that was terminated before completion, run by Diamond Headache Clinic. The registered enrollment target is 2 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05492695, a Phase 4 study, was terminated before completion, sponsored by Diamond Headache Clinic.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
This is a multicenter, double-blind, placebo-controlled study assessing the effectiveness of Galcanezumab as an add-on therapy for Migraine participants on a stable migraine prophylaxis regimen including Botox with or without one other migraine prophylaxis agent (BMPT), who have persistent unmet need. The study population will consist of approximately 150 participants ages 18-65 who report at least a 30% reduction in monthly migraine days from BMPT and still experience an average of ≥ 6 migraine days per month, following International Classification of Headache Disorders (ICHD-3) criteria. Subjects should be stable on at least 2, but no more than 8, consecutive injection cycles of Botox. Overall migraine day reduction will be assessed in the participants based on participant self-report (via daily electronic diaries) and medical record review.
Interventions
- OTHER Placebo
- DRUG Galcanezumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2022-10-01 |
| Est. Completion | 2023-09-28 |
| Phase | Phase 4 |
Why NCT05492695 stopped before completion
NCT05492695 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 2 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05492695 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05492695 about?
NCT05492695 is a clinical study titled "Tandem OnabotulinumtoxinA Galcanezumab Emerging Therapeutic Headache Elimination Research Study". This is a multicenter, double-blind, placebo-controlled study assessing the effectiveness of Galcanezumab as an add-on therapy for Migraine participants on a stable migraine prophylaxis regimen including Botox with or without one other migraine prophylaxis agent (BMPT), who have persistent unmet nee...
What is the current status of trial NCT05492695?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2022-10-01. Estimated completion is 2023-09-28.
What interventions are being tested in trial NCT05492695?
The interventions under investigation include: Placebo (OTHER), Galcanezumab (DRUG).
Who is sponsoring clinical trial NCT05492695?
This trial is sponsored by Diamond Headache Clinic, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05492695's enrollment target sits among peer trials
2 1998th of 2000 higher than 1 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI